Bakuchiol
Also known as Bakuchiol, (S)-(+)-Bakuchiol, 4-[(1E,3S)-3-Ethenyl-3,7-dimethylocta-1,6-dien-1-yl]phenol, Babchi extract active, Sytenol A
“No regulator has issued a verdict on this ingredient.”
Bakuchiol (CAS 10309-37-2; C18H24O; molecular weight 256.4 g/mol) is a meroterpene phenol (terpenophenol) isolated from the seeds of Psoralea corylifolia (also classified as Cullen corylifolium / babchi). It is marketed as a 'natural retinol alternative' because gene-expression profiling shows it functions as a retinol functional analog — upregulating collagen types I, III, IV and aquaporin 3 — despite having no structural resemblance to retinoids (Chaudhuri & Bojanowski, Int J Cosmet Sci 2014, PMID 24471735). The foundational head-to-head clinical trial (Dhaliwal et al., Br J Dermatol 2019, PMID 29947134) randomized 44 participants to 0.5% bakuchiol cream twice daily versus 0.5% retinol cream once daily for 12 weeks; both arms showed statistically equivalent reductions in wrinkle surface area and hyperpigmentation, but the retinol arm reported significantly more facial scaling and stinging, supporting bakuchiol's tolerability advantage. Bakuchiol has high photochemical and hydrolytic stability, allowing daytime use without the photodegradation concerns of topical retinoids. Two case reports of allergic contact dermatitis to bakuchiol (Malinauskiene 2019, PMID 30644106; Raison-Peyron 2020, PMID 31423588) document patch-test-confirmed sensitization to bakuchiol at 0.1%, establishing it as a (rare but real) contact allergen. The 2024 systematic review of human clinical trials (Fanning et al., J Drugs Dermatol 2024, PMID 38564402) examined 15 trials and concluded that the evidence base 'lacks methodologic rigor' — most studies were unblinded open-label, ten combined bakuchiol with other ingredients, and four did not specify dose — introducing high risk of bias. Bakuchiol is NOT in the CIR Quick Reference Table as of the December 2025 edition (verified absent across Sept 2022, Oct 2024, and Dec 2025 QRTs); no SCCS opinion exists; CosIng coverage cannot be directly verified due to JS-SPA limitation. Regulatory coverage gap is the dominant honest limitation.
Retinol-comparable efficacy with better tolerability: 12-week head-to-head RCT (Dhaliwal et al. 2019, PMID 29947134) showed 0.5% bakuchiol matched 0.5% retinol on wrinkle and hyperpigmentation reduction, with significantly less skin scaling and stinging — the foundational evidence for bakuchiol's positioning as a 'natural retinol alternative'
Functions as a retinol functional analog despite no structural similarity: gene-expression profiling shows bakuchiol upregulates collagen types I, III, IV and aquaporin 3 in skin models, plausibly via retinoic acid receptor pathways (Chaudhuri & Bojanowski 2014, PMID 24471735)
High photostability: unlike topical retinol (which degrades rapidly under UV exposure and is conventionally restricted to nighttime use), bakuchiol is photochemically and hydrolytically stable, enabling daytime application without photo-degradation concerns
Documented anti-aging clinical effects: improvements in fine lines, wrinkles, hyperpigmentation, elasticity, firmness, and overall photo-damage in 12-week topical studies (Chaudhuri & Bojanowski 2014, PMID 24471735); broader applications in acne and post-inflammatory hyperpigmentation reported in systematic review (Puyana et al. 2022, PMID 36176207)
No documented teratogenicity signal at cosmetic concentrations: in contrast to retinoids (where systemic vitamin A teratogenicity drives pregnancy contraindications), bakuchiol's chemical class does not carry a known teratogenic mechanism — though absence of evidence is not evidence of absence and pregnancy safety remains uncharacterized in controlled studies
- · No SCCS opinion exists — the European Commission's Scientific Committee on Consumer Safety has not assessed bakuchiol; EU regulatory boundary conditions are undefined
No CIR safety assessment exists as of December 2025 — bakuchiol is absent from the September 2022, October 2024, and December 2025 CIR Quick Reference Tables; the formal authoritative regulatory verdict that grounds most cosmetic-ingredient assessments has not been issued
Documented contact allergen: at least two patch-test-confirmed case reports of allergic contact dermatitis to bakuchiol at 0.1% (Malinauskiene 2019, PMID 30644106; Raison-Peyron 2020, PMID 31423588). Rare in absolute terms but contradicts marketing claims of universal hypoallergenicity; sensitization-prone consumers should patch test before facial use
Clinical evidence base has methodological weaknesses: 2024 systematic review (Fanning et al., PMID 38564402) of 15 human trials concluded 'high risk of bias' — 12 of 15 trials were unblinded open-label without controls, 10 combined bakuchiol with other actives confounding attribution, 4 did not specify dose. The retinol-comparable efficacy claims should be read against this evidence-quality caveat
Pregnancy and lactation safety not characterized: no controlled human safety studies in pregnant or lactating populations; the 'safer than retinol in pregnancy' marketing claim rests on absence of data rather than positive safety evidence
Source plant Psoralea corylifolia historically used in traditional medicine contains psoralens (furocoumarins) that ARE phototoxic; pure isolated bakuchiol is structurally distinct from psoralens and is not itself a furocoumarin, but quality control for residual psoralen contamination in commercial bakuchiol preparations is a formulation-grade concern not addressed by the cosmetic safety literature reviewed